Bvf Partners L. P/Il Sells 500,742 Shares of XOMA Co. (NASDAQ:XOMA) Stock

XOMA Co. (NASDAQ:XOMA) major shareholder Bvf Partners L. P/Il sold 500,742 shares of the stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The sale was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

XOMA Trading Up 0.1 %

XOMA opened at $26.50 on Thursday. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. The firm has a market cap of $312.17 million, a price-to-earnings ratio of -7.61 and a beta of 0.92. The business’s 50 day moving average is $27.99 and its two-hundred day moving average is $28.10. XOMA Co. has a 52 week low of $19.50 and a 52 week high of $35.00.

XOMA (NASDAQ:XOMA) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.05. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The business had revenue of $7.20 million during the quarter, compared to analysts’ expectations of $6.66 million. On average, research analysts predict that XOMA Co. will post -1.41 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have weighed in on XOMA. StockNews.com upgraded XOMA from a “sell” rating to a “hold” rating in a report on Thursday, January 16th. HC Wainwright reissued a “buy” rating and issued a $123.00 target price on shares of XOMA in a research report on Tuesday, January 7th.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC grew its holdings in shares of XOMA by 0.6% during the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock worth $4,840,000 after buying an additional 1,138 shares in the last quarter. Barclays PLC grew its stake in XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after buying an additional 8,447 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 795 shares in the last quarter. State Street Corp boosted its holdings in XOMA by 1.2% in the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock worth $3,783,000 after acquiring an additional 1,754 shares during the period. Finally, Ellsworth Advisors LLC purchased a new stake in XOMA during the 3rd quarter worth $516,000. Hedge funds and other institutional investors own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.